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Background: Use of manual thrombectomy during primary percutaneous coronary intervention
(primary PCI) and its effect on infarct size is still debatable.
Methods: 70 patients (30 patients with thrombectomy and 40 without) who underwent primary
PCI for ST-elevation myocardial infarction (STEMI) with adjunct intracoronary abciximab
between January 2007 and August 2013 and had CMR afterwards were included.oronary
y artery
pt. Fax:
154 M.A.H. Abdelhafez et al.Results: No significant difference in the baseline characteristics except for a higher baseline TnI
(11.6 ± 16.7 vs. 2.4 ± 7.9, P = 0.009) and more visible thrombus and or TIMI 0 flow
(P= 0.04) in the thrombectomy group. No significant difference was found in infarct size assessed
by CMR (18.1 ± 13.2 vs. 16.45 ± 11.7, P= 0.6) or peak TnI (75.9 ± 126 vs. 51.3 ± 50.4,
P= 0.26) between the two groups. A moderate positive correlation was found between Peak as well
as TnI at 24 hours (TnI-24 h) and CMR-determined infarct size (r = 0.5 and r = 0.7 respectively,
P< 0.001). TnI-24 h (B= 0.152, 95.0% Confidence Interval (CI) 0.116–0.187, P< 0.001) as well
as final TIMI grade (B= 10,848, 95.0% CI 15.109 to 6.587, P< 0.001) predicts infarct size.
Conclusions: In a retrospective real world cohort of patients with STEMI, no difference was found
in infarct size assessed by CMR or peak TnI between the groups with and without thrombectomy.
TnI-24 h as well as final TIMI flow predicts infarct size.
 2016 Egyptian Society of Cardiology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The presence of coronary thrombus during primary PCI has
been linked to lower post procedural TIMI flow (Thrombolysis
In Myocardial Infarction (TIMI) flow grade), decrease in
myocardial perfusion grade, no-reflow, and drug eluting stent
thrombosis.1 Microembolization can lead to the occlusion of
arterioles in the microcirculation thus impairing end myocar-
dial perfusion whereas embolization of larger atherosclerotic
particles can lead to the occlusion of pre-arterioles and side
branches leading to the phenomenon of no- or slow-
reflow.2,3 Several trials have shown that device-based removal
of thrombus from the coronary artery has an inconsistent
effect on reperfusion surrogate and clinical end points.4
Meta-analyses of adjunctive thrombectomy trials have
reported a definite improvement in surrogate markers of reper-
fusion.5 However, still there is a debate about the effect of
thrombus aspiration on the infarct size which appears to be
the most meaningful surrogate clinical end point in assessing
new therapeutic tools in the setting of acute myocardial infarc-
tion.6 We aimed to assess the effect of manual aspiration
thrombectomy with adjunct intracoronary abciximab during
primary PCI on infarct size by CMR and peak TnI levels in
a retrospective real world cohort of patients with STEMI.
Also, we have assessed the correlation between infarct sizes
by CMR and peak TnI levels.
2. Methods
2.1. Study design and population
We have searched our database for all patients who were
admitted for acute STEMI between January 2007 and August
2013 (n= 458 patients), with the culprit in a native coronary
artery (n= 435 patients) and who received adjunct intracoro-
nary abciximab (n= 198 patients) and, additionally, under-
went CMR examination afterward (n= 70 patients). Of
those patients, 30 patients were treated with manual thrombus
aspiration assisted primary PCI and another 40 without.
Infarct size was assessed in both groups by CMR and was
studied as the primary end point. Infarct size assessed by peak
serum TnI levels as well as its correlation with infarct size
assessed by CMR was studied as a secondary end point.2.1.1. Inclusion criteria
Patients with acute STEMI (defined by chest pain suggestive of
myocardial ischemia for at least 30 min, and an electrocardio-
graphic (ECG) with ST-segment elevation of >0.1 mV in P2
leads) referred for primary PCI within 24 h of symptom onset
were included.
2.1.2. Exclusion criteria
Patients who required intra-aortic balloon counter pulsation
or mechanical ventilation were excluded as were patients with
previous coronary artery bypass (CABG), patients with left
main coronary stenosis and patients who did not receive intra-
coronary abciximab.
2.1.3. Percutaneous coronary intervention (PCI) procedure
Medication consisted of 500 mg of aspirin I.V if aspirin was
not received before, a loading dose of an ADP receptor blocker
(clopidogrel, ticagrelor or prasugrel) and intracoronary abcix-
imab (0.25 mg/kg bolus was administered through the guiding
catheter without post procedure I.V infusion unless intra-
procedural thrombotic complications occurred). A heparin bolus
of 50–70 IU per kg was administered after sheath insertion,
with a repeat bolus (2000–5000 IU) when needed to maintain
an activated clotting time of >250 sec. PCI was performed
by standard techniques. After the lesion was crossed with the
guidewire, the use of manual thrombus aspiration was depend-
ing on the operator’s discretion. Aspiration was performed
using manual thrombectomy devices (EliminateTM aspiration
catheter and Quick-Cat Extraction Catheter). Then, a bare
metal or drug eluting stent was implanted either directly or
after predilation according to the operator’s discretion. Treat-
ment after PCI included aspirin 100 mg per day, ADP receptor
blockers (oral clopidogrel, ticagrelor, or prasugrel), beta-
blockers, lipid-lowering agents, and angiotensin-converting
enzyme inhibitors.
2.2. Thrombectomy catheters
The eliminateTM (TERUMO) is an aspiration catheter intended
for removing fresh, soft emboli and thrombus from vessels in
the coronary and peripheral vasculature. The Eliminate
catheter is a dual lumen rapid exchange catheter. Outside
diameter is proximally 1.40 mm, distally 1.70 mm and internal
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compatibility is 0.014 and guide catheter compatibility is 6F.7
The QuickCat extraction catheter (Spectranetics) has a dual
lumen with hydrophilic coating and an outside diameter prox-
imally 1.26 mm, distally 1.50 mm. Working Length 145 cm, rapid
exchange segment length 10 cm, radiopaque marker located
1 mm from the tip, crossing profile 4.5F/0.059, guidewire com-
patibility 0.014, Extraction lumen area 0.858 mm2, extraction
rate 1.16 mL/sec and guide catheter compatibility 6F.8
2.2.1. Cardiac magnetic resonance
Magnetic resonance imaging was performed with a 1.5- and
3 T systems (Siemens Healthcare; Erlangen; Germany). Axial
two dimensional half-Fourier acquisition single-shot turbo
spin-echo sequence (HASTE) images were used for an anatom-
ical overview and to locate the anatomical axes of the heart.
Balanced steady-state free precession cine sequences (voxel
size, 1.3  1.3  8 mm3), two-dimensional turbo inversion-
recovery magnitude T2-weighted imaging with short inversion
time (voxel size, 1.3  1.3  8 mm3), and late gadolinium-
enhanced (LGE) segmented two-dimensional inversion-
recovery turbo fast low-angle shot sequences performed
10 min after contrast agent injection (voxel size,
1.3  1.3  8 mm3) were acquired and prospectively synchro-
nized to the ECG. The type of Gadolinium-based contrast
agent used was Gadobutrol (Gadovist) and the average dose
used per patient was 0.2 mmol/kg. Left ventricular (LV) vol-
umes and global ejection fraction were calculated from manu-
ally drafted endocardial borders in end systole and endTable 1 Baseline clinical and angiographic characteristics.
Mean ± SD, mean ± standard deviation; n, number.
Baseline characteristics With
thrombectomy
Without
thrombectomy
P
value
n= 30 n= 40
Age, Years, mean ± SD 56.3 ± 10 59.6 ± 12 0.2
Male Sex, n (%) 20(67) 29(72) 0.6
Diabetes mellitus, n (%) 6(20) 9(23) 1
Hypertension, n (%) 23(77) 33(83) 0.5
Hypercholesterolemia, n
(%)
26(87) 33(83) 0.7
Current smoking, n (%) 13(43) 17(43) 0.9
Ex-smoker, n (%) 3(10) 8(20) 0.3
Body mass index, mean
± SD
27.4 ± 3.5 26.5 ± 4 0.3
Culprit artery, n (%) 0.5
Left anterior
descending
12(40) 21(53.5)
Left circumflex 4(13.3) 7(17.5)
Right coronary 14(46.7) 12(30)
Multivessel disease, n
(%)
19(63) 26(65) 0.8
Previous Myocardial
infarction, n (%)
1(3) 2(5) 1
Onset of symptoms to
balloon time, hours,
mean ± SD
6.5 ± 13.4 4.3 ± 5.4 0.9
Door to balloon time,
minutes, mean ± SD
49.6 ± 26 52.7 ± 20 0.59
TIMI flow 0 and/or
visible thrombus, n (%)
28(93.3) 30(75) 0.04
Direct stenting, n (%) 7(23.3) 16(40) 0.1diastole. LV mass (the area between the epicardial and endo-
cardial borders) was calculated using the CINE images
whereas the infarct area (the white area within the black myo-
cardium) was segmented on the delayed-enhancement CMR
images using a dedicated workstation (Centricity EnterpriseTM
PACS, GE Healthcare Pty Ltd Piscataway, NJ, USA). The
infarct size was calculated as percent of the left ventricular
myocardium in late enhancement images.9
2.2.2. Definitions
Transmural necrosis was considered as LGE comprising more
than 50% of the wall thickness in the respective segment.
Microvascular obstruction (MVO) was defined as dark areas
of absent contrast surrounded by LGE and was consequently
included in the total infarct size.10 Small MVO was defined as
patchy, non-confluent spots of MVO. Large MVO was defined
as confluent areas of MVO comprising large amount of the
infarct zone.11 Infarct size as percent of LV myocardium is
defined as large when P10% and small when <10%.12
2.2.3. Enzymatic infarct size
Troponin I levels (in ng/ml) were measured before primary
PCI, every 6 h for one day and then daily until discharge unless
repeated measurements are required according to the clinical
status of the patient.
2.2.4. Data collection and statistical analysis
Categorical variables were compared using the X2 test or Fish-
er’s exact test as appropriate. Continuous normally distributed
data were tested by Student’s t-test or, in the case of not-
normally distributed data, by a nonparametric test for inde-
pendent samples (Mann–Whitney U test). Multiple group
analysis was performed using one way ANOVA and post
hoc tests. Spearman’s correlation and multiple linear regres-
sion were done to determine the correlation between peak
TnI (reflecting the enzymatic infarct size) and infarct size
assessed by CMR as well as the predictors of infarct size.
Receiver-operator characteristic (ROC) curves were generated
using the dichotomous variable infarct size P10% or <10%
and optimal cutoff points for detection of large infarct size
were obtained using the Youden index. All analyses were per-
formed with SPSS 20.0 (SPSS, Inc., Chicago, IL, USA).Figure 1 Baseline troponin I levels. TnI, troponin I.
Figure 2 Infarct size assessed by cardiac magnetic resonance.
LV, left ventricle.
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70 patients (30 patients with aspiration thrombectomy assisted
primary PCI and 40 without) who underwent primary PCI for
STEMI in native coronary arteries between January 2007 and
August 2013 and had CMR afterward were included. There
was no statistically significant difference in the baseline charac-
teristics between patients including culprit artery (Table 1)
except for a higher baseline TnI in the thrombectomy group
(11.6 ± 16.7 vs. 2.4 ± 7.9, P= 0.009) (Fig. 1). The presence
of visible thrombus and or TIMI 0 flow was found to be more
evident in patients with thrombus aspiration (P= 0.04). There
was no significant difference regarding the rate of direct stent-
ing (i.e. without balloon predilatation) between the two groups
(p= 0.1). Also, there were no significant differences in the LV
end diastolic volume, end systolic volume and ejection fraction
assessed by echocardiography before discharge between the
two groups (p= 0.1, p= 0.8 and p= 0.9 respectively).
2.2.6. Infarct size assessed by CMR
Themean time between STEMI occurrence andCMR examina-
tion was 9.7 ± 8.7 days without differences between the two
groups. No statistically significant difference was found in the
infarct size assessed by CMR in the two groups (18.1 ± 13.2
vs. 16.45 ± 11.7, P= 0.6) (Fig. 2). Also, there was no statisti-Figure 3 Peak troponin I levels. TnI, troponin I.cally significant difference in the absolute infarct mass in grams
between the two groups (31.4 ± 28 vs. 28.1 ± 21.6, P= 0.5).
The extent of infarction (transmural vs. non transmural) was
not different in the two groups (P= 0.4). Also, there were no
significant differences in the LV end diastolic volume, end sys-
tolic volume and ejection fraction assessed by CMR between
the two groups (p= 0.8, p= 0.9 and p= 0.4 respectively).
The presence of MVO as well as its extent (small or large)
was also not different in the two groups (p= 0.8 and
p= 0.25 respectively). Three subgroups of patients were iden-
tified: (i) without MVO, (ii) small MVO and (iii) large MVO.
The one way ANOVA and post hoc tests for the correlation
between MVO and CMR-determined infarct size found that
the presence of MVO is associated with larger infarct size when
compared to no MVO (p= 0.001), but no statistically signifi-
cant difference in infarct size was found between patients with
small and large MVO (p= 0.2).
2.2.7. Peak TnI (reflecting the enzymatic infarct size)
Despite the higher baseline TnI in the thrombectomy group,
there was no statistically significant difference in peak TnI
levels between the two groups (75.9 ± 126 vs. 51.3 ± 50.4,
P= 0.26) (Fig. 3). There was also no statistically significant
difference in TnI-24 h levels between the two groups (med-
ian = 33 vs. 21.4, mean ± SD= 48.7 ± 56.4 vs. 48.5
± 54.2, P= 0.9).
2.2.8. Correlation between peaks TnI (reflecting the enzymatic
infarct size), TnI-24 h and CMR-determined infarct size
Since there was no significant difference in peak TnI levels,
TnI-24 h levels and CMR-determined infarct size between
patients in the two groups, all patients were merged into 1
cohort to determine the correlation between peak TnI, TnI-
24 h and CMR-determined infarct size. A moderate positive
correlation was found between TnI-24 h (r= 0.7, P< 0.001)Figure 4 The accuracy of TnI-24 h and Peak TnI in predicting
cardiac magnetic resonance-determined infarct size. TnI-24 h,
troponin I at 24 h; peak TnI, peak troponin I.
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assessed by CMR. CMR-determined infarct size was also
found to be correlated with the final TIMI flow grade
(r= .4, p= 0.001). The accuracy of TnI-24 h and Peak
TnI in predicting CMR-determined infarct size was examined
using ROC curve analyses (Fig. 4) and the area under the
curve for predicting large residual infarct size (P10%) was
0.82 (95% CI: 0.71 to 0.92; p< 0.001), and 0.85 (95% CI:
0.76 to 0.94; p< 0.001) respectively. TnI-24 h with cutoff
value of 19.2 ng/ml was found to have 73% sensitivity and
76% specificity in detecting large infarct size. Peak TnI with
cutoff value of 35.4 ng/ml, was found to have 75% sensitivity
and 86% specificity in detecting large infarct size. Multiple lin-
ear regression identified TnI-24 h (B= 0.152, 95.0% Confi-
dence Interval (CI) for B= 0.116–0.187, P< 0.001) as well
as final TIMI flow grade (B= 10,848, 95.0% CI for
B= 15.109 to 6.587, P< 0.001) as predictors of infarct
size assessed by CMR.
3. Discussion
The main findings in our study are as follows: (i) There was no
statistically significant difference in the infarct size or in abso-
lute infarct mass assessed by CMR between the two study
groups, and the presence of MVO but not its extent correlated
with the infarct size. (ii) There was also no statistically signif-
icant difference in the infarct size assessed by peak TnI
between the two groups despite the higher baseline TnI in
the thrombus aspiration group. (iii) There were no significant
differences in the LV end diastolic volume, end systolic volume
and ejection fraction assessed by echocardiography and CMR
between the two groups. (iv) There was however a moderate
positive correlation between peak TnI and TnI-24 h and
CMR-determined infarct size and peak TnI as well as TnI-
24 h was sensitive and specific for detecting large residual
infarct size. TnI-24 h and final TIMI flow grade were found
to be predictors of infarct size assessed by CMR.
In our study all patients received intracoronary abciximab
which was proven in INFUSE-AMI study to be beneficial in
decreasing the infarct size at 30 days in patients with large
anterior STEMI presenting early after symptom onset and
undergoing primary PCI with bivalirudin anticoagulation,
when delivered to the infarct lesion site.13 The use of intracoro-
nary abciximab is a routine daily practice in our center which
could to some extent explain the equivocal results in our study
despite the fact that in INFUSE AMI study the group with
thrombus aspiration plus intracoronary abciximab had the
lowest infarct size by CMR.13 The operators decided whether
or not to use the thrombus aspiration devices but the fact that
the tendency to use it in patients with large thrombus burden
or TIMI 0 flow was clear because the presence of visible
thrombus and/or TIMI 0 flow was frequently seen in the
thrombus aspiration group.
3.1. Infarct size assessed by CMR
Despite the fact that the majority of aspiration thrombectomy
randomized controlled trials (RCTs) found a statistically sig-
nificant improvement in one or a combination of surrogate
markers of myocardial reperfusion14, there are a inconsistent
data about the effect of thrombus aspiration on infarct sizewhich is probably the best surrogate end point in assessing
new therapeutic tools in the setting of acute myocardial infarc-
tion and allows for appreciable reductions in sample size com-
pared with alternative methods.6 In our study there was no
significant difference in the infarct size or in absolute infarct
mass between the two study groups taking into consideration
that patients in the thrombectomy group had higher baseline
TnI and higher thrombus burden with reduced TIMI flow
grade than the control group which is expected to be associ-
ated with a higher rate of reperfusion failure, larger myocar-
dial damage and infarct size. Despite that, the thrombectomy
group had a similar infarct size by CMR as compared to the
control group, which might suggest an actual benefit of man-
ual thrombectomy rather than a neutral effect putting in mind
that the total ischemic time was not statistically different
between the two groups. In the recent meta-analysis of over
5500 patients conducted by Kumbhani et al. no difference
was found in final infarct size or final ejection fraction between
the aspiration thrombectomy and PCI-only arms 15 and man-
ual aspiration thrombectomy was found to be beneficial in
reducing major adverse cardiac events, including mortality at
both 6 and 12 months.15 This benefit cannot be explained by
a reduction in infarction size.14 Besides, this meta-analysis
did not include two large recently published studies: TASTE
and TOTAL in which manual aspiration thrombectomy did
not reduce major adverse cardiac events.16,17
We did not find significant difference regarding the extent
of infarction (transmural vs. non-transmural) between the
two study groups. Also, the presence of MVO as well as its
extent (small or large) was not different in the two groups.
We did find that the presence of MVO is associated with larger
infarct size, but no statistically significant difference in infarct
size was found between those with small and large MVO. Sim-
ilar results have been shown in the study conducted by Małek
et al.11
3.2. Peak TnI (reflecting the enzymatic infarct size) and its
correlation with the CMR-determined infarct size
We have found no statistically significant difference in peak
TnI or TnI-24 h levels between the two study groups. Both
TAPAS and EXPIRIA trials showed also no significant differ-
ence in peak creatine kinase (CK) and CK-MB levels between
groups with and without thrombus aspiration.18,19 Ahmed
et al. have also found no significant difference in peak levels
of CK and troponin T (cTnT) in patients with and without
aspiration.20 In our study a moderate positive correlation
was found between peak TnI and TnI-24 h and CMR-
determined infarct size. Peak TnI as well as TnI-24 h was sen-
sitive and specific for detecting large residual infarct size. TnI-
24 h and final TIMI flow grade were found to be predictors of
infarct size assessed by CMR. Hassan et al. showed that peak
cTnT after primary PCI for STEMI offers a good estimation
of infarct size. The ROC curve cutoff value of Peak TnI to
detect large infarct in our study is a bit higher than that
showed in his trial probably by using different troponin
types.21 Similarly, Chia et al. showed that peak, and area under
time-concentration curve of CK, CK-MB, and troponins T
and I significantly correlated with infarct size and LV ejection
fraction. In particular, 72-h troponin I correlated strongly with
5-day and 30-day infarct size.12
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Our study is a single-center, non-randomized, retrospective
study but it represents the daily real world practice in an uns-
elected group of patients with STEMI. The fact that the oper-
ators chose when to perform (or not perform) thrombectomy,
could introduce bias into this comparison. Unfair comparison
and unequal ascertainment of the exposure were only 30
patients used in the intervention arm and 40 in control group
also add to the under-estimation of the effect of manual
thrombectomy and may lead to misleading results and diffi-
culty for globalization of the results. But, the quantification
of infarct size by DE-CMR is highly reproducible, and pro-
vides a useful surrogate end point for clinical trials with appre-
ciable reductions in sample size compared with alternative
methods. Also, lack of long-term follow-up is an important
limitation in our study.
3.4. Conclusions
In a real world cohort of STEMI patients, who underwent pri-
mary PCI with and without thrombectomy and who received
adjunct intracoronary abciximab, no difference was found in
the infarct size assessed by CMR or peak TnI levels between
the two groups despite the higher TnI levels in the thrombec-
tomy group at baseline. TnI-24 h as well as final TIMI flow
predicts infarct size.
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